A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Registration Number
- NCT04487080
- Lead Sponsor
- Janssen Research & Development, LLC
- Brief Summary
The purpose of this study is to assess the efficacy of the amivantamab and lazertinib combination, compared with osimertinib, in participants with epidermal growth factor receptor (EGFR) mutation (Exon 19 deletions \[Exon 19del\] or Exon 21 L858R substitution) positive, locally advanced or metastatic non-small cell lung cancer (NSCLC).
- Detailed Description
Worldwide, lung cancer is the most commonly diagnosed cancer. In NSCLC the most prevalent actionable driver mutations result in the activation of epidermal growth factor receptor (EGFR). Osimertinib and Lazertinib are EGFR tyrosine kinase inhibitors (TKIs). Amivantamab is a novel bispecific antibody that targets the extracellular domain of both EGFR and MET and can inhibit tumor growth driven by EGFR and mesenchymal-epithelial transition (MET) receptors. Lazertinib inhibits primary activating Exon 19dell and Exon 21 L858R substitution EGFR mutations, and the EGFR T790M+ resistance mutation. The hypothesis is that the amivantamab and lazertinib combination (Arm A) will demonstrate superior PFS compared with single-agent osimertinib (Arm B). The study consists of 3 phases: Screening Phase, Treatment Phase and Follow-up Phase. Participants will undergo response evaluation criteria in solid tumors (RECIST 1.1), pharmacokinetics, and safety evaluations (adverse events, laboratory tests, vital sign measurements, physical examinations).
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 1074
- Participant must have newly diagnosed histologically or cytologically confirmed, locally advanced or metastatic non-small cell lung cancer (NSCLC) that is treatment naive and not amenable to curative therapy including surgical resection or chemoradiation
- The tumor harbors exon 19 deletions (Exon 19del) or Exon 21 L858R substitution, as detected by an food and drug administration (FDA)-approved or other validated test in a clinical laboratory improvement amendments (CLIA) certified laboratory (sites in the United states [US]) or an accredited local laboratory (sites outside of the US) in accordance with site standard of care
- Mandatory submission of unstained tissue from tumor (in a quantity sufficient to allow for central analysis of EGFR mutation status and blood (for circulating tumor deoxyribonucleic acid [ctDNA], digital droplet polymerase chain reaction [ddPCR], and pharmacogenomic analysis)
- Any toxicities from prior anticancer therapy must have resolved to common terminology criteria for adverse events (CTCAE) Grade 1 or baseline level
- Participant must have at least 1 measurable lesion, according to response evaluation criteria in solid tumors (RECIST) v1.1 that has not been previously irradiated. Measurable lesions should not have been biopsied during screening, but if only 1 non-irradiated measurable lesion exists, it may undergo a diagnostic biopsy and be acceptable as a target lesion, provided the baseline tumor assessment scans are performed at least 14 days after the biopsy
- Participant has received any prior systemic treatment at any time for locally advanced Stage III or metastatic Stage IV disease (adjuvant or neoadjuvant therapy for Stage I or II disease is allowed, if administered more than 12 months prior to the development of locally advanced or metastatic disease)
- Participant has an active or past medical history of leptomeningeal disease
- Participant with untreated spinal cord compression. A participant that has been definitively treated with surgery or radiation and has a stable neurological status for at least 2 weeks prior to randomization is eligible provided they are off corticosteroid treatment or receiving low-dose corticosteroid treatment less than or equal to (<=) 10 milligrams per day (mg/day) prednisone or equivalent
- Participant has an active or past medical history of interstitial lung disease (ILD)/pneumonitis, including drug-induced or radiation ILD/pneumonitis
- Participant has known allergy, hypersensitivity, or intolerance to the excipients used in formulation of amivantamab, lazertinib, or osimertinib, or any contraindication to the use of osimertinib
- Participant has symptomatic brain metastases. A participant with asymptomatic or previously treated and stable brain metastases may participate in this study
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib Lazertinib Participants will receive lazertinib 240 mg (80\*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily. Treatment Arm C (Double-blind): Lazertinib+Placebo Osimertinib Placebo Participants will receive lazertinib 240 mg (80\*3) orally once daily plus matching placebo of osimertinib 80 mg orally once daily. Treatment Arm A (Open-label): Amivantamab and Lazertinib Amivantamab Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (\<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (\>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80\*3) orally once daily. Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib Placebo Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80\*3) orally once daily. Treatment Arm B (Double-blind): Osimertinib+Placebo Lazertinib Osimertinib Participants will receive osimertinib 80 mg orally once daily plus matching placebo of lazertinib 240 mg (80\*3) orally once daily. Treatment Arm A (Open-label): Amivantamab and Lazertinib Lazertinib Participants will receive amivantamab 1050 milligram (mg) intravenously (IV) for body weight less than (\<) 80 kilogram (kg) and 1400 mg for body weight greater than or equal to (\>=) 80 kg in 28-day cycles: once weekly in Cycle 1 (with a split dose on Days 1-2), and then every 2 weeks in subsequent cycles. Lazertinib will be administered 240 mg (80\*3) orally once daily.
- Primary Outcome Measures
Name Time Method Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) From randomization to either disease progression or death whichever occurs first (up to 32.8 months) PFS was defined as the time from randomization until the date of objective disease progression based on BICR using RECIST version 1.1 or death (by any cause) the absence of progression, whichever came first. Disease progression was defined using RECIST 1.1 as a 20 percent (%) increase in the sum of diameters of target measurable lesions above the smallest sum observed, with a minimum absolute increase of 5 millimeters (mL). Participants who have not progressed or have not died at the time of analysis were censored at the time of the latest date of their last evaluable RECIST version 1.1 assessment.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (266)
Sir Run Run Shaw Hospital Zhejiang University School of Medicine
🇨🇳Hangzhou, China
Centrum Onkologii im Prof F Lukaszczyka
🇵🇱Bydgoszcz, Poland
Arizona Oncology Associates, PC - HAL
🇺🇸Goodyear, Arizona, United States
Yuma Regional Medical Center
🇺🇸Yuma, Arizona, United States
City of Hope Long Beach Elm
🇺🇸Long Beach, California, United States
University of California Irvine
🇺🇸Orange, California, United States
Rocky Mountain Cancer Centers
🇺🇸Lone Tree, Colorado, United States
Cancer Specialists of North Florida
🇺🇸Jacksonville, Florida, United States
University Cancer And Blood Center LLC
🇺🇸Athens, Georgia, United States
East Jefferson General Hospital
🇺🇸Metairie, Louisiana, United States
Maryland Oncology Hematology, PA
🇺🇸Columbia, Maryland, United States
Henry Ford Hospital
🇺🇸Detroit, Michigan, United States
Minnesota Oncology Hematology P A
🇺🇸Edina, Minnesota, United States
Mayo Clinic
🇺🇸Rochester, Minnesota, United States
Washington University School Of Medicine
🇺🇸Saint Louis, Missouri, United States
Astera Cancer Care
🇺🇸East Brunswick, New Jersey, United States
Willamette Valley Cancer Institute and Research Center
🇺🇸Eugene, Oregon, United States
University of Pittsburgh Medical Center
🇺🇸Pittsburgh, Pennsylvania, United States
Sarah Cannon Research Institute
🇺🇸Nashville, Tennessee, United States
Texas Oncology P A
🇺🇸Austin, Texas, United States
Oncology Consultants Texas
🇺🇸Houston, Texas, United States
Virginia Cancer Specialists
🇺🇸Fairfax, Virginia, United States
Centro Oncológico Korben
🇦🇷Buenos Aires, Argentina
Instituto Alexander Fleming
🇦🇷Buenos Aires, Argentina
Hospital Privado Centro Medico de Cordoba
🇦🇷Cordoba, Argentina
Centro Oncologico Riojano Integral (Cori)
🇦🇷La Rioja, Argentina
Clínica Viedma
🇦🇷Viedma, Argentina
Flinders Medical Centre
🇦🇺Bedford Park, Australia
Austin Hospital
🇦🇺Heidelberg, Australia
Cabrini Medical Centre
🇦🇺Malvern, Australia
St John of God Hospital Murdoch
🇦🇺Murdoch, Australia
Sir Charles Gairdner Hospital
🇦🇺Nedlands, Australia
Westmead Hospital
🇦🇺Westmead, Australia
Southern Medical Day Care Centre
🇦🇺Wollongong, Australia
Princess Alexandra Hospital
🇦🇺Woolloongabba, Australia
Cliniques Universitaires Saint Luc
🇧🇪Bruxelles, Belgium
Grand Hopital De Charleroi Site Les Viviers
🇧🇪Charleroi, Belgium
UZ Leuven
🇧🇪Leuven, Belgium
Clinique Saint Pierre
🇧🇪Ottignies, Belgium
Algemeen Ziekenhuis Delta
🇧🇪Roeselare, Belgium
Fundacao Pio XII
🇧🇷Barretos, Brazil
Cetus Oncologia
🇧🇷Belo Horizonte, Brazil
Ynova Pesquisa Clinica
🇧🇷Florianopolis, Brazil
Oncosite - Centro de Pesquisa Clínica em Oncologia Ltda
🇧🇷Ijui, Brazil
Liga Norte Riograndense Contra O Cancer
🇧🇷Natal, Brazil
UPCO Unidade de Pesquisa Clinica em Oncologia
🇧🇷Pelotas, Brazil
Irmandade Santa Casa de Misericordia de Porto Alegre
🇧🇷Porto Alegre, Brazil
Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS
🇧🇷Porto Alegre, Brazil
Ministerio da Saude Instituto Nacional do Cancer
🇧🇷Rio De Janeiro, Brazil
Oncoclinicas Rio de Janeiro S A
🇧🇷Rio de Janeiro, Brazil
Instituto D Or de Pesquisa e Ensino IDOR
🇧🇷Rio de Janeiro, Brazil
Fundacao Faculdade de Medicina Instituto do Cancer do Estado de Sao Paulo
🇧🇷Sao Paulo, Brazil
Fundacao Antonio Prudente A C Camargo Cancer Center
🇧🇷Sao Paulo, Brazil
Núcleo de Pesquisa São Camilo
🇧🇷Sao Paulo, Brazil
IOS - Instituto de Oncologia de Sorocaba Dr. Gilson Delgado
🇧🇷Sorocaba, Brazil
Hospital Evangélico de Cachoeiro de Itapemirim
🇧🇷Vitoria, Brazil
William Osler Health System
🇨🇦Brampton, Ontario, Canada
Juravinski Cancer Centre
🇨🇦Hamilton, Ontario, Canada
The Ottawa Hospital Cancer Centre
🇨🇦Ottawa, Ontario, Canada
McGill University Health Centre
🇨🇦Montreal, Quebec, Canada
Beijing Friendship Hospital Capital Medical University
🇨🇳Beijing, China
Beijing Cancer Hospital
🇨🇳Beijing, China
Chinese PLA General Hospital
🇨🇳Beijing, China
Beijing Chest hospital, Capital medical university
🇨🇳Beijing, China
Jilin cancer hospital
🇨🇳Changchun, China
Hunan Cancer hospital
🇨🇳Changsha, China
The First People's Hospital Of Changzhou
🇨🇳Changzhou, China
Sichuan Cancer Hospital
🇨🇳Chengdu, China
West China Hospital Sichuan University
🇨🇳Chengdu, China
Southwest Hospital
🇨🇳ChongQing, China
The First Affiliated Hospital Sun Yat sen University
🇨🇳Guang Zhou, China
Sun Yat-Sen Memorial Hospital Sun Yat-sen University
🇨🇳Guangzhou, China
Zhejiang Cancer Hospital
🇨🇳Hang Zhou, China
Second Affiliated Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, China
The Second Affiliated Hospital of Zhejiang University College of Medicine
🇨🇳Hangzhou, China
Harbin medical university cancer hospital
🇨🇳Harbin, China
Huizhou Municipal Central Hospital
🇨🇳Huizhou, China
Taizhou Hospital of Zhejiang Province
🇨🇳Linhai, China
Nantong Tumor Hospital
🇨🇳Nantong, China
Ruijin Hospital Shanghai Jiao Tong University
🇨🇳Shanghai, China
Shanghai Chest Hospital
🇨🇳Shanghai, China
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Shanghai East Hospital
🇨🇳Shanghai, China
Shengjing Hospital Of China Medical University
🇨🇳Shenyang, China
Tianjin Medical University General Hospital
🇨🇳Tianjin, China
Cancer Hospital of Xinjiang Medical University
🇨🇳Urumchi, China
The First Affiliated Hospital of Wenzhou Medical University
🇨🇳Wenzhou, China
TongJi Hospital of TongJi Medical College of Huazhong University of Science & Technology
🇨🇳Wuhan, China
The First Affiliated Hospital of Xian Jiaotong University
🇨🇳XI An, China
Yantai Yuhuangding Hospital
🇨🇳Yantai, China
Henan Cancer Hospital
🇨🇳Zhengzhou, China
Institut Bergonie
🇫🇷Bordeaux, France
Hospices Civils de Lyon HCL
🇫🇷Bron, France
CHU de Grenoble Hopital Albert Michallon
🇫🇷La Tronche, France
Institute Coeur Poumon
🇫🇷Lille, France
CHU de Limoges
🇫🇷Limoges, France
Hopital Nord
🇫🇷Marseille Cedex 20, France
Institut Curie
🇫🇷Paris, France
Hopital Tenon
🇫🇷Paris, France
CHU Bordeaux
🇫🇷Pessac, France
CHU Nantes
🇫🇷Sain-Herblain, France
HIA Begin
🇫🇷Saint Mande, France
CHU Bretonneau
🇫🇷Tours, France
Institut Gustave Roussy
🇫🇷Villejuif Cedex, France
Zentralklinik Bad Berka GmbH
🇩🇪Bad Berka, Germany
Helios Klinikum Emil von Behring GmbH
🇩🇪Berlin, Germany
Universitaetsklinikum Essen
🇩🇪Essen, Germany
Asklepios Klinik Gauting GmbH - Asklepios Fachkliniken Munchen-Gauting
🇩🇪Gauting, Germany
Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
🇩🇪Halle (Saale), Germany
Thoraxklinik am Universitatsklinikum Heidelberg
🇩🇪Heidelberg, Germany
Onkologische Schwerpunktpraxis
🇩🇪Heilbronn, Germany
Kliniken der Stadt Koeln gGmbH
🇩🇪Koeln, Germany
POIS Leipzig GbR
🇩🇪Leipzig, Germany
Pius-Hospital Oldenburg
🇩🇪Oldenburg, Germany
Robert-Bosch-Krankenhaus - Klinik Schillerhoehe
🇩🇪Stuttgart, Germany
Orszagos Koranyi Tbc es Pulmonologiai Intezet
🇭🇺Budapest, Hungary
Veszprém Megyei Tudőgyógyintézet
🇭🇺Farkasgyepü, Hungary
Mátrai Gyógyintézet-Bronchológia
🇭🇺Gyöngyös, Hungary
Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
🇭🇺Szekesfehervar, Hungary
Markusovszky Egyetemi Oktatokorhaz
🇭🇺Szombathely, Hungary
Tudogyogyintezet Torokbalint
🇭🇺Torokbalint, Hungary
Basavatarakam Indo-American Hospital
🇮🇳Hyderabad, India
Tata Medical Center
🇮🇳Kolkata, India
Tata Memorial Hospital
🇮🇳Mumbai, India
HCG Manavta Cancer Centre
🇮🇳Nasik, India
Noble Hospital Pvt Ltd
🇮🇳Pune, India
Rambam Health Corporation
🇮🇱Haifa, Israel
Hadassah Medical Center
🇮🇱Jerusalem, Israel
Meir Medical Center
🇮🇱Kfar Saba, Israel
Rabin Medical Center
🇮🇱Petah Tikva, Israel
Chaim Sheba Medical Center
🇮🇱Ramat Gan, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel-Aviv, Israel
Ospedale San Giuseppe Moscati di Avellino
🇮🇹Avellino, Italy
Azienda Ospedaliero Univ. Policlinico Gaspare Rodolico
🇮🇹Catania, Italy
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
🇮🇹Meldola, Italy
Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico
🇮🇹Milano, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milano, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
🇮🇹Milano, Italy
Istituto Europeo di Oncologia
🇮🇹Milano, Italy
San Gerardo Hospital
🇮🇹Monza, Italy
Ospedale Monaldi
🇮🇹Napoli, Italy
Aou San Luigi Gonzaga
🇮🇹Orbassano, Italy
Ospedale S. Maria Delle Croci
🇮🇹Ravenna, Italy
Irccs Gemelli
🇮🇹Roma, Italy
Istituto Clinico Humanitas
🇮🇹Rozzano, Italy
Juntendo University Hospital
🇯🇵Bunkyo Ku, Japan
National Cancer Center Hospital
🇯🇵Chuo Ku, Japan
National Hospital Organization Kyushu Medical Center
🇯🇵Fukuoka, Japan
National Hospital Organization Himeji Medical Center
🇯🇵Himeji, Japan
Kansai Medical University Hospital
🇯🇵Hirakata, Japan
Kanazawa University Hospital
🇯🇵Kanazawa, Japan
National Cancer Center Hospital East
🇯🇵Kashiwa, Japan
Kurume University Hospital
🇯🇵Kurume, Japan
Matsusaka Municipal Hospital
🇯🇵Matsusaka, Japan
Niigata Cancer Center Hospital
🇯🇵Niigata, Japan
Okayama University Hospital
🇯🇵Okayama, Japan
Kindai University Hospital
🇯🇵Osaka Sayama shi, Japan
National Hospital Organization Shibukawa Medical Center
🇯🇵Shibukawa, Japan
The Cancer Institute Hospital of JFCR
🇯🇵Tokyo, Japan
National Hospital Organization Tokyo Medical Center
🇯🇵Tokyo, Japan
Ehime University Hospital
🇯🇵Toon-shi, Japan
National Hospital Organization Osaka Toneyama Medical Center
🇯🇵Toyonaka-shi, Japan
Wakayama Medical University Hospital
🇯🇵Wakayama, Japan
National Hospital Organization Iwakuni Clinical Center
🇯🇵Yamaguchi, Japan
National Hospital Organization Yamaguchi Ube Medical Center
🇯🇵Yamaguchi, Japan
Inje University Haeundae Paik Hospital
🇰🇷Busan, Korea, Republic of
Chungbuk National University Hospital
🇰🇷Cheongju-si, Korea, Republic of
Seoul National University Bundang Hospital
🇰🇷Seongnam-si, Korea, Republic of
Kangbuk Samsung Hospital
🇰🇷Seoul, Korea, Republic of
Severance Hospital Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
Asan Medical Center
🇰🇷Seoul, Korea, Republic of
Samsung Medical Center
🇰🇷Seoul, Korea, Republic of
The Catholic University of Korea Seoul St Mary s Hospital
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Pulau Pinang
🇲🇾George Town, Malaysia
Hospital Sultan Ismail
🇲🇾Johor Bahru, Malaysia
Hospital Kuala Lumpur
🇲🇾Kuala Lumpur, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Malaysia
Hospital Tengku Ampuan Afzan
🇲🇾Kuantan, Malaysia
Beacon Hospital Sdn Bhd
🇲🇾Petaling Jaya, Malaysia
Mexico Centre for Clinical Research, S.A. de C.V.
🇲🇽Ciudad de Mexico, Mexico
Médica Sur
🇲🇽Ciudad de Mexico, Mexico
Hospital Civil de Guadalajara Fray Antonio Alcalde
🇲🇽Guadalajara, Mexico
CIMOVA, Morals Vargas Centro de Investigación SC
🇲🇽Leon, Mexico
Health Pharma Professional Research
🇲🇽Mexico, Mexico
Instituto Nacional de Cancerologia
🇲🇽Mexico, Mexico
i Can Oncology Center
🇲🇽Monterrey, Mexico
Oncologia Integral Satelite
🇲🇽Naucalpan, Mexico
Rijnstate Ziekenhuis
🇳🇱Arnhem, Netherlands
Ziekenhuis St Jansdal
🇳🇱Harderwijk, Netherlands
UMC Radboud
🇳🇱Nijmegen, Netherlands
Jeroen Bosch Ziekenhuis
🇳🇱s-Hertogenbosch, Netherlands
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Poland
Szpitale Pomorskie Sp z o o
🇵🇱Gdynia, Poland
Warminsko-Mazurskie Centrum Chorob Pluc w Olsztynie
🇵🇱Olsztyn, Poland
Private Specialist Hospitals - MedPolonia
🇵🇱Poznan, Poland
Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Uls Santa Maria - Hosp. Pulido Valente
🇵🇹Lisboa, Portugal
Uls Santo Antonio - Hosp. Santo Antonio
🇵🇹Porto, Portugal
Hosp. Cuf Porto
🇵🇹Porto, Portugal
Instituto Portugues de Oncologia
🇵🇹Porto, Portugal
Pan American Center for Oncology Trials LLC
🇵🇷Rio Piedras, Puerto Rico
Irkutsk Regional Oncology Dispensary
🇷🇺Irkutsk, Russian Federation
Moscow City Oncology Hospital № 62
🇷🇺Krasnogorsk, Russian Federation
Krasnoyarsk Regional Oncology Dispensary
🇷🇺Krasnoyarsk, Russian Federation
Leningrad Regional Oncology Dispensary
🇷🇺Kuzmolovsky, Russian Federation
MCK
🇷🇺Moscow, Russian Federation
City Clinical Hospital #1
🇷🇺Nalchik, Russian Federation
Nizhny Novgorod Regional Oncological Dispensary
🇷🇺Nizhniy Novgorod, Russian Federation
Omsk Clinical Oncology Dispensary
🇷🇺Omsk, Russian Federation
Current medical technologies
🇷🇺Saint Petersburg, Russian Federation
N.N. Petrov Research Institute Of Oncology
🇷🇺Saint Petersburg, Russian Federation
Oncology Medical Clinics AV Medical group
🇷🇺St-Petersburg, Russian Federation
Tambov Regional Oncology Clinical Dispansary
🇷🇺Tambov, Russian Federation
Tomsk Cancer Research Institute
🇷🇺Tomsk, Russian Federation
Bashkir State Medical University
🇷🇺Ufa, Russian Federation
Yaroslavl Regional Clinical Oncology Hospital
🇷🇺Yaroslavl, Russian Federation
Hosp Univ A Coruna
🇪🇸A Coruna, Spain
Inst. Cat. D'Oncologia-Badalona
🇪🇸Badalona, Spain
Hosp. de La Santa Creu I Sant Pau
🇪🇸Barcelona, Spain
Hosp. Univ. Quiron Dexeus
🇪🇸Barcelona, Spain
Hosp Univ Vall D Hebron
🇪🇸Barcelona, Spain
Hosp. Univ. de Burgos
🇪🇸Burgos, Spain
Institut Català D'Oncologia Girona
🇪🇸Girona, Spain
Hosp. Gral. Univ. Gregorio Maranon
🇪🇸Madrid, Spain
Hosp. Univ. 12 de Octubre
🇪🇸Madrid, Spain
Hosp. Univ. La Paz
🇪🇸Madrid, Spain
Hosp. Univ. Pta. de Hierro Majadahonda
🇪🇸Majadahonda, Spain
Hosp Regional Univ de Malaga
🇪🇸Malaga, Spain
Clinica Univ. de Navarra
🇪🇸Pamplona, Spain
Hosp. Virgen Del Rocio
🇪🇸Seville, Spain
Hosp. Gral. Univ. Valencia
🇪🇸Valencia, Spain
Hosp. Clinico Univ. Lozano Blesa
🇪🇸Zaragoza, Spain
Kaohsiung Medical University Chung Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
E-DA Hospital
🇨🇳Kaohsiung, Taiwan
Chang Gung Medical Foundation
🇨🇳Kaohsiung, Taiwan
Taipei Medical University Shuang Ho Hospital
🇨🇳New Taipei, Taiwan
Chung Shan Medical University Hospital
🇨🇳Taichung, Taiwan
China Medical University Hospital
🇨🇳Taichung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei City, Taiwan
Phramongkutklao Hospital and Medical College
🇹🇭Bangkok, Thailand
Siriraj Hospital
🇹🇭Bangkok, Thailand
Chiang Mai University
🇹🇭Chiangmai, Thailand
Songklanagarind Hospital, Prince of Songkla University
🇹🇭Songkla, Thailand
Adana City Hospital
🇹🇷Adana, Turkey
Başkent University Medical Faculty Adana Application and Research Center
🇹🇷Adana, Turkey
Gazi University Hospital
🇹🇷Ankara, Turkey
Ankara Bilkent City Hospital
🇹🇷Ankara, Turkey
Istanbul Universitesi Cerrahpasa Tip Fakultesi Ic Hastaliklari Anabilim Dali Medikal Onkoloji Bd
🇹🇷Istanbul, Turkey
Medipol Mega University Hospital
🇹🇷Istanbul, Turkey
T C Saglik Bakanlıgi Goztepe Prof Dr Suleyman Yalcın Sehir Hastanesi
🇹🇷Istanbul, Turkey
Medical Point
🇹🇷Izmir, Turkey
Necmettin Erbakan University Meram Medical Faculty
🇹🇷Konya, Turkey
Trakya University Medical Faculty
🇹🇷Edirne, Turkey
Dnipropetrovsk State Medical Academy, Dnipropetrovsk City Multifield Clinical Hospital # 4
🇺🇦Dnipro, Ukraine
Municipal non-profit enterprise 'Regional Center of Oncology'
🇺🇦Kharkiv, Ukraine
National Cancer Institute
🇺🇦Kyiv, Ukraine
Medical Center 'Ok Clinic' of LLC 'International Institute of Clinical Studies'
🇺🇦Kyiv, Ukraine
Municipal Oncology Centre of Uzhgorod Central Municipal Clinical Hospitlal
🇺🇦Uzhgorod, Ukraine
Edinburgh Cancer Centre Western General
🇬🇧Edinburgh, United Kingdom
UCL Cancer Institute
🇬🇧London, United Kingdom
Chelsea And Westminster Hospital
🇬🇧London, United Kingdom
The Royal Marsden NHS Trust
🇬🇧Sutton, United Kingdom
Christie NHS Foundation Trust
🇬🇧Manchester, United Kingdom
Nottingham University Hospitals NHS Trust
🇬🇧Nottingham, United Kingdom